Alopexx, Inc.

General Information

We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections.

In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine’s broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases.

Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation.

Note: Alopexx says it has not generated any revenue. Net loss is for the 12 months that ended Sept. 30, 2022.

**Note: As of Sept. 30, 2022, Alopexx had an accumulated deficit of $6.65 million.

**Note: As of Dec. 31, 2023, Alopexx reported a net loss of $3.78 million on essentially no revenue.

Alopexx says that it has three officers and no employees before the IPO, according to the prospectus.

(Note: On Dec. 26, 2023, Alopexx revived the IPO and kept the terms the same, according to an S-1/A filing.)

(Note: Alopexx increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. **This IPO had been set for pricing on Oct. 20, 2022, but the deal was delayed. **By February 2023, the Alopexx IPO  had been revived. But the IPO wound up getting postponed around Feb. 15, 2023. Previous terms: Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is “ALPX”. On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.)


Industry: Pharmaceuticals
Employees: 0
Founded: 2006
Contact Information
Address 186 Alewife Brook Pkwy #1068 Cambridge, Massachusetts 02138
Phone Number (617) 780-1598
Web Address
View Prospectus: Alopexx, Inc.
Financial Information
Market Cap $39.24mil
Revenues $0 mil (last 12 months)
Net Income $-3.78 mil (last 12 months)
IPO Profile
Symbol ALPX
Exchange NASDAQ
Shares (millions): 3.0
Price range $5.00 - $5.00
Est. $ Volume $15.0 mil
Manager / Joint Managers ThinkEquity
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change